Visuospatial deficits characterize Pisa syndrome and not Camptocormia in Parkinson’s disease
Objective: We performed a multicenter, case-control study with the aim to analyze cognitive differences between parkinsonian patients with Pisa syndrome or camptocormia and matched controls…Impact of the delayed diagnosis in the prognosis of Parkinson’s disease.
Objective: To evaluate the difference of motor and non-motor dysfunction, and quality of life in Parkinson’s disease (PD) patients with and without delayed diagnosis. Background:…Structural MRI features of glucocerebrosidase (GBA)-associated Parkinson’s disease
Objective: To compare structural differences in brain magnetic resonance imaging (MRI) between Glucocerebrosidase (GBA) mutation carriers with Parkinson’s disease (PD-GBA) vs non-mutation carriers. Background: PD-GBA…Cerebellar and other motor symptoms in Huntington’s Disease: A multiple scale correlation study
Objective: To describe the cerebellar symptoms and other accompanying movement disorders in Huntington's Disease (HD). Background: HD is a pathological entity whose etiological substrate is…Multi-modal MRI features and their relationship with clinical scales in Parkinson disease and Atypical Parkinsonian Syndromes
Objective: To compare MRI sings and volumetric measurements in Parkinson disease (PD), Progressive Supranuclear Palsy (PSP), and Multiple System Atrophy (MSA) and their relationship with…Learning to PERSEVERE: Efficacy and Feasibility of Peer Mentor Support and Caregiver Education in Lewy Body Dementia
Objective: To examine the effects of peer mentoring on caregiving mastery, Lewy Body Dementia (LBD) knowledge, and dementia attitudes among LBD family caregivers. Background: Few…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…The Effect of Oropharyngeal Resting Tremor on Swallow Timings in a Clinical Cohort of People with Parkinson’s Disease
Objective: The objective of the project was to investigate how the presence of resting tremors in oropharyngeal structures impacted swallow timings and duration measures to…A randomized controlled trial comparing the efficacy and safety of pyridostigmine versus midodrine for the treatment of orthostatic hypotension in Parkinson’s disease patients
Objective: To assess the long-term efficacy and safety of pyridostigmine and midodrine in the treatment of OH in PD. Background: In Parkinson's disease (PD), orthostatic…Movement disorders with phosphodiesterase 10A IgG autoimmunity
Objective: To report four new cases of phosphodiesterase 10A (PDE10A) IgG neurological autoimmunity. Background: PDE10A IgG was recently identified as a biomarker of paraneoplastic neurological…
- « Previous Page
- 1
- …
- 90
- 91
- 92
- 93
- 94
- …
- 153
- Next Page »